Diethylstilboestrol: I, pharmacology, toxicology and carcinogenicity in humans

European Journal of Cancer

Volumn 28, Issue 6-7, 1992, Pages 1182-1189

  Marselos, M ^b   Tomatis, L ^a  

^a INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^b UNIVERSITY OF IOANNINA   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

DIETHYLSTILBESTROL;

ADULT; ARTICLE; CANCER RISK; CARCINOGENICITY; DRUG TOXICITY; FEMALE; FETUS; HUMAN; MALE; NONHUMAN; PRIORITY JOURNAL; TESTIS CANCER; VAGINA CARCINOMA;

ABNORMALITIES, DRUG-INDUCED; ADOLESCENT; ADULT; CARDIOVASCULAR DISEASES; CHILD; DIETHYLSTILBESTROL; ENVIRONMENTAL EXPOSURE; FEMALE; GENITALIA; HUMAN; MALE; NEOPLASMS; PREGNANCY; PRENATAL EXPOSURE DELAYED EFFECTS; SUPPORT, NON-U.S. GOV'T;

EID: 0026659367     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/0959-8049(92)90482-H     Document Type: Article

References (146)

1. Zur Physiologie und Pathologie der Ovarialfunktion
2. THE OVARY AND THE ENDOCRINOLOGIST
3. The bearing of recent research on the sex hormones on clinical obstetrics and gynaecology
4. OESTRUS-PRODUCING HORMONES
5. The practical outcome of recent research on hormones
6. The Oestrogenic Activity of some Condensed-Ring Compounds in Relation to their other Biological Activities
7. Synthetic oestrogenic agents without the phenanthrene nucleus (letter to the editor)
8. Stilboestrol: biochemistry and discovery
9. THE THERAPEUTIC USE OF ESTROGENIC SUBSTANCES
10. Estrogen and progestin metabolism in pregnant women. With special reference to preeclamptic toxemia and the effect of hormone administration
11. THE USE OF STILBESTROL FOR THE TREATMENT OF THREATENED AND HABITUAL ABORTION AND PREMATURE LABOR: A PRELIMINARY REPORT
12. THE RELATIONSHIP BETWEEN HORMONAL ABNORMALITIES AND ACCIDENTS OF LATE PREGNANCY IN DIABETIC WOMEN
13. Increased excretion of pregnanediol in pregnancy from diethylstilbestrol with special reference to the prevention of late pregnancy accidents.
14. Diethylstilbestrol in the prevention and treatment of complications of pregnancy.
15. Does the administration of diethylstilbestrol during pregnancy have therapeutic value?
16. Diethylstilbestrol: A review of its toxicity and use as a growth promotant in food-producing animals
17. Adenocarcinoma of the vagina. Association of maternal stilbestrol therapy with tumor appearance in young women
18. Clear cell adenocarcinoma of the cervix after maternal treatment with synthetic estrogens
19. Diethylstilbestrol in pregnancy. Frequency of exposure and usage patterns
20. Overview of perinatal and multigeneration carcinogenesis
21. Estrogens and Progestins
22. Diethylstilbestrol usage: Its interesting past, important present and questionable future
23. L'utilisation du diethylstilbestrol (DES) et ses effets sur la santé des consommateurs et leurs enfants
24. The influence of oral administration of diethylstilbestrol to beef cattle
25. Physiological effects of estrogens in animal feeds with emphasis on growth of ruminants
26. The anabolic effect of estrogens in nitrogenmetabolism of growing and finishing cattle and sheep
27. Gynaecomastia in stilboestrol workers
28. Diethylstilbestrol absorption in industry: a test for early detection as an aid in prevention
29. Metabolism of tritiumlabeled diethylstilbestrol by steers
30. Estrogenic activity of feces and urine following oral administration of diethylstilbestrol to lambs
31. Estrogen excretion by cows after oral administration of diethylstilbestrol
32. Biotransformation of diethylstilbestrol in the rhesus monkey and the chimpanzee
33. Comparative metabolism of diethylstilbestrol in the mouse, rhesus monkey, and chimpanzee
34. Disposition of diethylstilboestrol in the rhesus monkey
35. Further observations on the similarity of stilboestrol and natural oestrogenic agents
36. Metabolic activation of carcinogenic diethylstilbestrol in rodents and humans
37. Hyperestrogenism in workers in pharmaceutical establishment and their children as occupational disease
38. Effect of oestrogens and progestogens on liver function in the puerperium
39. Effect of long-term estrogen treatment on liver function in patients with prostatic carcinoma
40. Treatment and survival of patients with cancer of the prostate
41. Estrogen treatment for cancer of the prostate: early results with three doses of diethylstilbestrol and placebo
42. Body blood and electrolyte balance during estrogen therapy of prostatic cancer
43. Genotoxic effects of estrogens
44. Elevated 8-hydroxydeoxyguanosine levels in DNA of diethylstilbestrol-treated Syrian hamsters: Covalent DNA damage by free radicals generated by redox cycling of diethylstilbestrol
45. Testing of known carcinogens and noncarcinogens for their ability to induce unscheduled DNA synthesis in HeLa cells
46. Diethylstilbestrol induces metaphase arrest and inhibits microtubule assembly
47. Post-stilbestrol secondary syndrome
48. Vaginal and cervical abnormalities, including clear-cell adenocarcinoma, related to prenatal exposure to stilbestrol
49. Pathology and pathogenesis of diethylstilbestrol-related disorders of the female genital tract
50. Follow-up study of male and female offspring of DES-treated mothers. A preliminary report
51. Cytologic findings in female and male offspring of DES treated mothers
52. Prenatal exposure to stilbestrol. A prospective comparison of exposed female offspring with unexposed controls
53. Genital tract anomalies and cancer in females exposed in utero to diethylstilbestrol. Brief report on the DESAD Project
54. Vaginal epithelial changes in young women enrolled in the National Cooperative Diethylstilbestrol Adenosis (DESAD) project
55. Vaginal bleeding and diethylstilbestrol exposure during pregnancy: Relationship to genital tract clear cell adenocarcinoma and vaginal adenosis in daughters
56. Cellular detection of vaginal adenosis
57. Natural history of vaginal adenosis in women exposed to diethylstilbestrol in utero
58. The use of cellular studies in the investigation of the DES-exposed woman
59. Nuclear DNA study of vaginal and cervical squamous cell abnormalities in DES exposed progeny
60. The problem of squamous neoplasia in female DES progeny
61. Squamous cell dysplasia and carcinoma in situ of the cervix and vagina after prenatal exposure to diethylstibestrol
62. Microglandular hyperplasia in vaginal adenosis associated with oral contraceptives and prenatal diethylstilbestrol exposure
63. Upper genital tract changes associated with exposure in utero to diethylstilbestrol
64. Pathological semen and anatomical abnormalities of the genital tract in human male subjects exposed to diethylstilbestrol in utero
65. In utero exposure to diethylstilbestrol: Adverse effects on the reproductive tract and reproductive performance in male and female offspring
66. Reproductive history of women exposed to diethylstilbestrol in utero
67. Upper genital tract changes and infertility in diethylstilbestrol-exposed women
68. Infertility among daughters either exposed or not exposed to diethylstilbestrol
69. Fertility and outcome of pregnancy in women exposed in utero to diethylstilbestrol
70. Reproductive outcome of women exposed to diethylstilbestrol in utero
71. Intractable primary infertility in women exposed to diethylstilbestrol in utero
72. Adenocarcinoma of the vagina in adolescence. A report of 7 cases including 6 clear-cell carcinomas (socalled mesonephromas)
73. Vaginal cancer after maternal treatment with synthetic estrogens
74. Ageincidence and risk of diethylstilbestrol-related clear cell adenocarcinoma of the vagina and cervix
75. Clear-cell adenocarcinoma (“mesonephroma”) of the vagina. Three cases associated with maternal synthetic nonsteroid estrogen therapy
76. Stilbestrol and urogenital tract cancer in adolescents and young adults
77. Clear cell carcinoma of the cervix and vagina in young women
78. Stilboestrol therapy in pregnancy. Relationship to vaginal neoplasia in offspring
79. Prenatal stilbestrol experience in mothers of young cancer patients
80. Clear-cell adenocarcinoma of the vagina in a girl whose mother had taken diethylstilbestrol
81. A case of primary adenocarcinoma of the vagina and pregnancy (Sp.)
82. Ein Fall von Adenokarzinom der Vagina nach Diaethylstilboestrol-Exposition in utero
83. Use of sex hormones during pregnancy in Spain (Sp.)
84. Mesonephric carcinoma of the cervix uteri in an 8-year-old girl treated by hysterectomy
85. Increased incidence of cervical and vaginal dysplasia in 3 980 diethylstilbestrol-exposed young women—experience of the national collaborative diethystilbestrol adenosis project
86. Clear-cell vaginal adenocarcinoma in young girls. A personal observation (Fr.)
87. [Vaginal carcinoma in a young woman].
88. Vaginal cancer composed of clear cells found in a girl aged 18 years whose mother was treated during pregnancy by diethylstilbestrol (Agostilban) (Cz.)
89. Clear-cell adenocarcinoma of the vagina and cervix in girls: analysis of 170 Registry cases
90. Ageincidence and risk of diethylstilbestrol-related clear cell adenocarcinoma of the vagina and cervix
91. A survey of the use of oestrogens during pregnancy in the United Kingdom and of the genito-urinary cancer mortality and incidence rates in young people in England and Wales
92. Epidemiologic and clinical aspects of clear cell adenocarcinoma in young women
93. Rates and risks of diethylstilbestrol-related clear-cell adenocarcinoma of the vagina and cervix
94. Abnormal development of the human genital tract following prenatal exposure to diethylstilbestrol
95. Epidemiological studies of the effects of diethylstilboestrol
96. Risk factors for the development of diethylstilbestrol-associated clear cell adenocarcinoma: a case control study
97. Epidemiologic aspects and factors related to survival in 384 Registry cases of clear cell adenocarcinoma of the vagina and cervix
98. Diethylstilbestrol-related clear-cell adenocarcinoma in women with initial examinations demonstrating no malignant disease
99. Transition of benign vaginal adenosis to clear cell carcinoma
100. Diethylstilbestrol-associated vaginal adenosis followed by clear cell adenocarcinoma
101. Clear-cell adenocarcinoma of the vagina and cervix in young females: analysis of 37 tumors that persisted or recurred after primary therapy
102. Mesonephric carcinoma of the cervix uteri: a clinical and pathologic study
103. Clear cell “mesonephric” carcinoma of uterine cervix
104. Vaginal lesions of adenomatous origin
105. Diethylstilbestrol and clear cell vaginal carcinoma
106. Diethylstilbestrol and clear cell vaginal carcinoma
107. Diethylstilbestrol and clear cell vaginal carcinoma
108. Endometrial Adenocarcinoma After In Utero Diethylstilbesterol Exposure
109. Maternal diethylstilboestrol and ovarian malignancy in offspring
110. Prolactin-secreting pituitary adenoma: occurrence following prenatal exposure to diethylstilbestrol
111. Adenosquamous carcinoma of the cervix in a woman exposed to diethylstilbestrol in utero.
112. A randomised double-blind controlled trial of the value of stilboestrol therapy in pregnancy: long-term follow-up of mothers and their offspring
113. Seminoma and epididymal cysts in a young man with known diethylstilboestrol exposure in utero
114. Epidemiological studies of perinatal carcinogenesis
115. Risk factors for cancer of the testis in young men
116. The epidemiology of testicular cancer in young adults
117. Estrogen exposure during gestation and risk of testicular cancer
118. Prenatal and perinatal risk factors for testicular cancer
119. Hormonal risk factors in testicular cancer
120. Endometrial carcinoma after stilbestrol therapy in gonadal dysgenesis
121. Endometrial carcinoma in Turner's syndrome
122. Endometrial carcinoma associated with Sheehan's syndrome and stilbestrol therapy
123. Endometrial carcinoma following estrogen therapy for breast cancer. Report of three cases
124. A twenty-five-year follow-up study of women exposed to diethylstilbestrol during pregnancy
125. Randomized trial of high doses of stilbestrol and ethisterone in pregnancy: long-term follow-up of mothers
126. Breast cancer in mothers given diethylstilbestrol in pregnancy
127. Cancer risk among women exposed to exogenous estrogens during pregnancy
128. Breast cancer in DES-exposed mothers. Absence of association
129. Metastases, stimulating mammary cancer, in prostatic carcinoma under estrogenic therapy
130. Carcinoma of the prostate with metastases to breasts and testiscritical review of the literature and report of a case
131. Carcinoma of the breast under estrogen treatment for prostatic carcinoma (Ger.)
132. Hepatoma after prolonged estrogen therapy
133. Hepatoma associated with diethylstilbestrol therapy for prostatic carcinoma
134. Angiosarcoma of the liver associated with diethylstilbestrol
135. Hemangioendothelial sarcoma of the liver associated with long-term estrogen therapy in a man
136. Is malignant melanoma an endocrine-dependent tumor? The possible adverse effect of estrogen
137. Estrogen-induced hypernephroma
138. Oestrogen-induced renal carcinoma
139. Tumors of female offspring of mice exposed prenatally to diethylstilbestrol
140. Animal models of prenatal exposure to diethylstilboestrol
141. Occurrence of tumours in the descendants of CBA male mice prenatally treated with diethylstilbestrol